The Role of Bacillus Calmette-Guérin in the Treatment of Non-Muscle-Invasive Bladder Cancer

European Urology

Volumn 57, Issue 3, 2010, Pages 410-429

  Gontero, Paolo ^a   Bohle, Andreas ^b   Malmstrom, Per Uno ^c   O'Donnell, Michael A ^d   Oderda, Marco ^a   Sylvester, Richard ^e   Witjes, Fred ^f  

^a UNIVERSITY OF TURIN   (Italy)

^b HELIOS AGNES KARLL HOSPITAL   (Germany)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF IOWA   (United States)

^e EORTC DATA CENTER   (Belgium)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BCG; Bladder cancer; Dosing; Intravesical; Maintenance; Prognostic factors; Progression; Recurrence; Side effects; Survival; Tolerability; Toxicity

Indexed keywords

BCG VACCINE;

BLADDER CANCER; BLADDER DISEASE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTRACTURE; CYSTITIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; EPIDIDYMITIS; FEVER; FLU LIKE SYNDROME; HEMATURIA; HUMAN; INFECTION; LOWER URINARY TRACT SYMPTOM; LUNG COMPLICATION; PRIORITY JOURNAL; PROSTATITIS; RASH; REVIEW; SEPSIS; SYSTEMATIC REVIEW; URETHRITIS;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 74649087382     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.11.023     Document Type: Review

References (92)

1. Brandau S., and Suttman H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 61 (2007) 299-305
2. Galfano A., and Novara G. Methodological bases for systematic reviews. J Androl Sci 15 (2008) 1-9
3. Phillips B, Ball C, Sackett D, et al. Levels of evidence. Oxford Centre for Evidence-based Medicine Web site. http://www.cebm.net/levels_of_evidence.asp. Updated March 2009.
4. Herr H.W., and Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 179 (2008) 53-56
5. Sylvester R., Van der Meijden A., and Lamm D. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
6. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180-183
7. Ojea A., Nogueira J.L., Solsona E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
8. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al. Club Urológico Español de Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against the recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
9. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
10. Van der Meijden A.P.M., Sylvester R.J., Oosterlinck W., Hoeltl W., and Bono A.V. Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 44 (2003) 429-434
11. Bassi P., Spinadin R., Carando R., Balta G., and Pagano F. Modified induction course: a solution to side-effects?. Eur Urol 37 Suppl 1 (2000) 31-32
12. Zlotta A.R., van Vooren J.P., Huygen K., et al. What is the optimal regimen for BCG intravesical therapy? Are six week instillations necessary?. Eur Urol 37 (2000) 470-477
13. De Boer E.C., Rooyakkers S.J., Schamhart D.H.J., de Reijke T.M., and Kurth K.-H. BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur Urol 48 (2005) 333-338
14. Bui T.T., and Schellhammer P.F. Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 49 (1997) 687-690
15. De Reijke T.M., Kurth K.H., Sylvester R.J., et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group phase III trial. J Urol 173 (2005) 405-409
16. Sylvester R.J., Van der Meijden A., Witjes J.A., et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66 Suppl 1 (2005) 90-107
17. Herr H.W., and Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169 (2003) 1706-1708
18. Andius P., Fehrling M., and Holmang S. Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 96 (2005) 1290-1293
19. De Boer E.C., De Jong W.H., Steerenberg P.A., et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 34 (1992) 306-312
20. Winters W.D., and Lamm D.L. Antibody responses to bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. Cancer Res 41 (1981) 2672-2676
21. Fernandez-Gomez J., Solsona E., Unda M., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53 (2008) 992-1002
22. Pansadoro V., Emiliozzi P., De Paula F., Scarpone P., Pansadoro A., and Sternberg C. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. Urology 59 (2002) 227-231
23. Malmstrom P.-U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009) 247-256
24. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
25. Herr H.W. Is maintenance bacillus Calmette-Guérin really necessary?. Eur Urol 54 (2008) 971-973
26. Hall M.C., Chang S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178 (2007) 2314-2330
27. Shelley M.D., Wilt T.J., Court J., Coles B., Kynaston H., and Mason M.D. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumor-recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004) 485-490
28. Han R.F., and Pan J.G. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67 (2006) 1216-1223
29. Friedrich M.G., Pichlmeier U., Schwaibold H., Conrad S., and Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52 (2007) 1123-1130
30. Bohle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-687
31. Huncharek M., and Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a meta-analytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 27 (2004) 522-528
32. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
33. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
34. Patard J.-J., Rodriguez A., Leray E., Rioux-Leclercq N., Guillé F., and Lobel B. Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 41 (2002) 635-642
35. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., and Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169 (2003) 96-100
36. Denzinger S., Fritsche H.-M., Otto W., Blana A., Wieland W.-F., and Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 53 (2008) 146-152
37. Thalmann G.N., Markwalder R., Shahin O., Burkhard F.C., Hochreiter W.W., and Studer U.E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J Urol 172 (2004) 70-75
38. Gardmark T., Jahnson S., Wahlquist R., Wijkstrom H., and Malmstrom P.U. Analysis of progression and survival after 10 years of a randomized prospective study comparing mytomicin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int 99 (2007) 817-820
39. Hurle R., Losa A., Manzetti A., and Lembo A. Intravesical bacille Calmette-Guérin in stage 1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54 (1999) 258-263
40. Baniel J., Grauss D., Engelstein D., and Sella A. Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 52 (1998) 785-789
41. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-years outcome. Br J Urol 80 (1997) 762-765
42. Sylvester R.J., Van der Meijden A.P., Witjes J.A., and Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86-92
43. Schrier B.P.h., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A.L.M., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292-296
44. DeVeale B., Brummel T., and Seroude L. Immunity and aging: the enemy within?. Aging Cell 3 (2004) 195-208
45. Joudi F., Smith B., and O'Donnell M.A. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348
46. Herr H.W. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology 70 (2007) 65-68
47. Rischmann P., Desgrandchamps F., Malavaud B., and Chopin D.K. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37 Suppl 1 (2000) 33-36
48. Koya M.P., Simon M.A., and Soloway M.S. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 175 (2006) 2004-2010
49. Koga H., Kuroda M., Kudo S., et al. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol 12 (2005) 145-151
50. Saint F., Irani J., Patard J.J., et al. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 57 (2001) 883-888
51. Malmstrom P.U., Wijkstrom H., Lundholm C., Wester K., Busch C., and Norlén B.J. 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161 (1999) 1124-1127
52. Gonzalez O.Y., Musher D.M., Brar I., et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 36 (2003) 140-148
53. Heiner J.G., and Terris M.K. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. Urol Oncol 26 (2008) 137-140
54. Bilen C.Y., Inci K., Erkan I., and Ozen H. The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin. J Urol 169 (2003) 1702-1705
55. Van der Meijden A., Brausi M., Zambon V., et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 166 (2001) 476-481
56. Colombel M., Saint F., Chopin D., Malavaud B., Ludovic N., and Rischmann P. ITB01 Study Group. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176 (2006) 935-939
57. O'Donnell M. Does ofloxacin protect against BCG-related toxic effects in patients with bladder cancer?. Nat Clin Pract Urol 4 (2007) 304-305
58. Andius P., and Holmang P. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 93 (2004) 980-984
59. Palou J., Angerri O., Segarra J., et al. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 76 (2003) 1514-1516
60. Yossepowitch O., Eggener S., Bochner B., Donat M., Herr H., and Dalbagni G. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol 176 (2006) 482-485
61. Witjes J.A., Palou J., Soloway M., et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 7 (2008) 667-674
62. Morgia G., Falsaperla M., Madonia M., et al. Use of BCG in immunotherapy of superficial bladder cancer: multicentric investigation on safety and compliance. Urooncology 2 (2003) 129-135
63. Vegt P., Van der Meijden A., Sylvester R., et al. Does isoniazide reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 303911. J Urol 157 (1997) 1246-1249
64. Losa A., Hurle R., and Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 163 (2000) 68-72
65. Pagano F., Bassi P., Piazza N., Abatangelo G., Drago Ferrante G.L., and Milani C. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 27 Suppl 1 (1995) 19-22
66. Bassi P., Volpe A., Racioppi M., D'Agostino D., Gardi M., Totaro A., Pinto F., Sacco E., and Bongiovanni L. Methodology of superficial bladder cancer trials: objective evaluation of treatment - the need for standardization. Urol Int 83 (2009) 258-263
67. Mack D., Holtl W., Bassi P., et al. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol 165 (2001) 401-403
68. Martinez-Pineiro J.A., Flores N., Isorna S., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
69. Agrawal M.S., Agrawal M., Bansal S., Agarwal M., Lavania P., and Goyal J. The safety and efficacy of different doses of bacillus Calmette-Guérin in superficial bladder transitional cell carcinoma. Urology 70 (2007) 1075-1078
70. Takashi M., Wakai K., Hattori T., et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol 33 (2002) 41-47
71. Andius P., Damm O., and Holmang S. Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin. Scand J Urol Nephrol 38 (2004) 285-290
72. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J., et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 45 (2004) 606-612
73. Lebret T., Becette V., Hervé J.M., et al. Prognostic value of MIB-1 antibody labelling index to predict response to Bacillus Calmette-Guérin therapy in high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 37 (2000) 654-659
74. Peyromaure M., Weibing S., Sebe P., et al. Prognostic value of P53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy. Urology 59 (2002) 409-413
75. Saint F., Le Frere Belda M.-A., Quintela R., et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette-Guérin (BCG). Eur Urol 45 (2004) 475-482
76. Esuvaranathan K., Chiong E., Thamboo T.P., et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 109 (2007) 1097-1105
77. Cormio L, Tolve I, Annese P, et al. Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol. In press. doi:10.1016/j.urolonc.2008.08.003.
78. Thalmann G.N., Sermier A., Rentsch C., Mohrle K., Cecchini M.G., and Studer U.E. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164 (2000) 2129-2133
79. Kumar A., Dubey D., Bansal P., Mandhani A., and Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 168 (2002) 2232-2235
80. Gallagher B., Joudi F., Maymi J., and O'Donnell M.A. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology 71 (2008) 297-301
81. O'Donnell M.A., Lilli K., and Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2B for superficial bladder cancer. J Urol 172 (2004) 888-893
82. Lam J., Benson M., O'Donnell M.A., et al. Bacillus Calmette-Guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21 (2003) 354-360
83. Punnen S.P., Chin J.L., and Jewett M.A. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol 10 (2003) 1790-1795
84. O'Donnell M.A., Krohn J., and DeWolf W. Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 166 (2001) 1300-1305
85. Luciani L., Neulander E., Murphy W., and Wajsman Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology 58 (2001) 376-379
86. Bilen C., Ozen H., Tuncay F., Aygun C., Ekici S., and Kendi S. Clinical experience with BCG alone versus BCG plus epirubicin. Int J Urol 7 (2000) 206-209
87. Tozawa K., Okamura T., Sasaki S., et al. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not contraindicated for superficial bladder cancer. Urol Int 67 (2001) 289-292
88. Cai T., Nesi G., Tinacci G., et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 180 (2008) 110-115
89. Witjes J.A., Caris C.T.M., Mungan N.A., Debruyne F.M.J., and Witjes W.P.J. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin alone in patients with superficial bladder cancer. J Urol 160 (1998) 1668-1672
90. Kaasinen E., Rintala E., Pere A.K., et al. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-α2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J Urol 164 (2000) 47-52
91. Kaasinen E., Wijkström H., Malmstrom P.-U., et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of urinary bladder: a Nordic study. Eur Urol 43 (2003) 637-645
92. Di Stasi S.M., Giannantoni A., Giurioli A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7 (2006) 43-51